Biopharmaceutical company Inotek Pharmaceuticals Corporation announced yesterday that results from it Phase 2 study of its trabodenoson product candidate for patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) has been published in the Journal of Ocular Pharmacology and Therapeutics.
Called “A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma," the journal article reportedly shows that 50 to 500 mcg ocular doses of trabodenoson were well-tolerated and showed a dose-related reduction in IOP that was statistically significant and clinically relevant at 500 mcg in patients with POAG or OHT. Additionally, no clinically meaningful ocular or systemic side effects were identified.
Click here to read the full press release.
Source: Inotek Pharmaceuticals Corporation